Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200771 | 0.89 | ERN1 (0.40) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL22200577 | 0.89 | ERN1 (0.49) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL22200366 | 0.86 | ERN1 (0.47) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL25034102 | 0.85 | ERN1 (0.55) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL22200568 | 0.84 | ERN1 (0.41) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL22200582 | 0.82 | PIK3CA (0.43) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL22200612 | 0.79 | RORC (0.35) | ERN1BRAFBTK | |
| SCHEMBL22200701 | 0.78 | ERN1 (0.42) | ERN1BRAFBTKEGFRFGFR1 | |
| SCHEMBL22200371 | 0.78 | PIK3CA (0.38) | BRAFBTKEGFRFGFR1SRC | |
| SCHEMBL25034168 | 0.77 | ERN1 (0.68) | ERN1BRAFBTKEGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |